To the question of complex treatment of endometriosis

In: Reproductive Endocrinology · 2015 · vol. 0(23) , pp. 28 · doi:10.18370/2309-4117.2015.23.28-33 · W1776936293
article OA: diamond CC0 ⤵ 1 in-corpus citation
AI-generated summary by gemini-2.5-flash-lite, 2026-06-10

This study investigated proliferation and apoptosis markers in endometriosis lesions and found that the drug Epigalin, when added to dienogest, controls endometrial cell proliferative potential.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text

The paper examined proliferation and apoptosis in endometriosis lesions using immunohistochemical markers, studying 35 patients with internal endometriosis (adenomyosis), 52 with external genital endometriosis, and 19 with extragenital endometriosis. It reported low apoptosis and high proliferative activity with an endometrium-type proliferative pattern, suggesting prevalence of endometrial hyperplasia. In a second phase, antiproliferative effects of the drug Epigalin were assessed in 38 patients with adenomyosis and marked pain syndrome, comparing dienogest alone versus dienogest plus Epigalin, and finding Epigalin use helped control proliferative potential of endometrium cells. This paper is centrally about endometriosis — specifically evaluating antiproliferative treatment (Epigalin) and immunohistochemical proliferation/apoptosis features in endometriosis, including adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Work on improving the quality of antiproliferative treatment of endometriosis with regard morphological and immunohistochemical data was performed.At the first phase of the study the activity of proliferation markers and apoptosis markers in patients with various forms of endometriosis were studies: in 35 patients with internal endometriosis (adenomyosis), 52 patients with external genital endometriosis and 19 patients with extragenital endometriosis. As a result, it was found that in the lesions of endometriosis there are low apoptosis, high cell proliferative activity and proliferative endometrium type is prevalent (endometrial hyperplasia).At the second phase of the study antiproliferative properties of drug Epigalin in the treatment of endometriosis were assessment. 38 patients with adenomyosis and marked pain syndrome participated in a study: 18 patients received dienogest and 20 patients received dienogest and administered Epigalin. The result revealed that Epigalin use in the treatment of endometriosis allows controlling proliferative potential of the endometrium cells.
Full text 5,102 characters · extracted from oa-doi-fallback · click to expand
To the question of complex treatment of endometriosis DOI: https://doi.org/10.18370/2309-4117.2015.23.28-33Keywords: endometriosis, antiproliferative treatment, immunohistochemical studies, EpigalinAbstract Work on improving the quality of antiproliferative treatment of endometriosis with regard morphological and immunohistochemical data was performed. At the first phase of the study the activity of proliferation markers and apoptosis markers in patients with various forms of endometriosis were studies: in 35 patients with internal endometriosis (adenomyosis), 52 patients with external genital endometriosis and 19 patients with extragenital endometriosis. As a result, it was found that in the lesions of endometriosis there are low apoptosis, high cell proliferative activity and proliferative endometrium type is prevalent (endometrial hyperplasia). At the second phase of the study antiproliferative properties of drug Epigalin in the treatment of endometriosis were assessment. 38 patients with adenomyosis and marked pain syndrome participated in a study: 18 patients received dienogest and 20 patients received dienogest and administered Epigalin. The result revealed that Epigalin use in the treatment of endometriosis allows controlling proliferative potential of the endometrium cells. References - Adamyan, L.V., Kulakov, V.I. Endometriosis. Moscow. Medicine (1998): 317 p. - Kudrina, E.A., Ishchenko, A.I., Gadaeva, I.V., Shadyev, A.H., Kogan, E.A. “Molecular and biological characteristics of external genital endometriosis.” Obstetrics and gynecology, 6(2000): 24–27. - Sidorova, I.S., Kogan, E.A., Zayratiants, O.V., Unanian, A.L., Levakov, S.A. “A new look at the nature of endometriosis (adenomyosis).” Obstetrics and Gynecology, 3(2002): 32–38. - Tatarchuk, T.F., Kalugina, L.V. “Issue of prevention and treatment of hormonehyperproliferative diseases in women.” Women's Health, 7(2013): 51–57. - A shok, B.T., Chen, Y.G., Liu, X., Garikapaty, V.P., Seplowitz, R., et al. “Multiple molecular targets of indole-3carbinol, a chemopreventive anti-estrogen in breast cancer.” Eur J Cancer Prev, 11(2002): 86–93. - A uborn, K.L., Fan, S., Rosen, E.M., Goodwin L., et al. “Indole-3-carbinol is a negative regulator of estrogen.” J Nutr, 133(2003): 2470–2475. - C hatterji, U., Riby, J.E., Taniguchi, Т., Bjeldanes, E.X., et al. “Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells.” Carcinogeneses, 1 (Vol. 1) (2004): 119–1128. - Darai, E., Detchev, R., Hugol, D., Quang, N. T. “Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.” Hum Reprod, 18(2003): 1681–1685. - Dmowski, W.P., Ding, J., Shen, J., Rana, N., Fernandez, B.B., Braun D.P. “Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis.” Hum Reprod, 16(2001): 1802–1808. - Firestone, G.L., Bjeldanes, L.F. “Indole-3-carbinol and З-З-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp 1 transcription factor interactions.” J Nutr, 133(2003): 2448–2455. - M asuda, M., Suzuki, M., Lim, J.T.E., Weinstein, I.E. “Epigallocatechin-3-gallate inhibits activation of HER -2/neu and downstream signaling pathways in human heat and neck and breast carcinoma cells.” Clin Cancer Res, 9(2003): 3486–3491. - R ahman, K.M., Aranha, O., Sarkar, F.H. “Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epitelial cells.” Nutr Cancer, 45(2003): 101–112. - R eed, G.A., Peterson, K.S., Smith, H.J., Gray, J.C., Sullivan, D.K., et al. “A phase I study of indole-3-carbinol in women: tolerability and effects.” Cancer Epidemiol Biomarkers Prev, 8(2005). - Scholzen, Т., Gerdes, J. “The Ki-67 protein: from the know and the unknown.” J Cell Physiol, 3(2000): 311–312. - Thangapazham, R.L., Singh, A.K., Sharma, A., et.al. “Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.” Cancer Lett, 8(2007): 832–841. Downloads Published How to Cite Issue Section License Copyright (c) 2015 Н. Ф. Захаренко, Н. В. Коваленко, І. П. Маноляк This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (1)

References (10)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK